Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Apr 7:342:d1875.
doi: 10.1136/bmj.d1875.

Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort

Affiliations
Randomized Controlled Trial

Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort

Robyn A North et al. BMJ. .

Abstract

Objectives: To develop a predictive model for pre-eclampsia based on clinical risk factors for nulliparous women and to identify a subgroup at increased risk, in whom specialist referral might be indicated.

Design: Prospective multicentre cohort.

Setting: Five centres in Auckland, New Zealand; Adelaide, Australia; Manchester and London, United Kingdom; and Cork, Republic of Ireland.

Participants: 3572 "healthy" nulliparous women with a singleton pregnancy from a large international study; data on pregnancy outcome were available for 3529 (99%).

Main outcome measure: Pre-eclampsia defined as ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg, or both, on at least two occasions four hours apart after 20 weeks' gestation but before the onset of labour, or postpartum, with either proteinuria or any multisystem complication. Preterm pre-eclampsia was defined as women with pre-eclampsia delivered before 37(+0) weeks' gestation. In the stepwise logistic regression the comparison group was women without pre-eclampsia.

Results: Of the 3529 women, 186 (5.3%) developed pre-eclampsia, including 47 (1.3%) with preterm pre-eclampsia. Clinical risk factors at 14-16 weeks' gestation were age, mean arterial blood pressure, body mass index (BMI), family history of pre-eclampsia, family history of coronary heart disease, maternal birth weight, and vaginal bleeding for at least five days. Factors associated with reduced risk were a previous single miscarriage with the same partner, taking at least 12 months to conceive, high intake of fruit, cigarette smoking, and alcohol use in the first trimester. The area under the receiver operating characteristics curve (AUC), under internal validation, was 0.71. Addition of uterine artery Doppler indices did not improve performance (internal validation AUC 0.71). A framework for specialist referral was developed based on a probability of pre-eclampsia generated by the model of at least 15% or an abnormal uterine artery Doppler waveform in a subset of women with single risk factors. Nine per cent of nulliparous women would be referred for a specialist opinion, of whom 21% would develop pre-eclampsia. The relative risk for developing pre-eclampsia and preterm pre-eclampsia in women referred to a specialist compared with standard care was 5.5 and 12.2, respectively.

Conclusions: The ability to predict pre-eclampsia in healthy nulliparous women using clinical phenotype is modest and requires external validation in other populations. If validated, it could provide a personalised clinical risk profile for nulliparous women to which biomarkers could be added. Trial registration ACTRN12607000551493.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; RAN and PNB have had consultancy relationships with Pronota in the previous three years; RAN has a consultancy relationship with Alere; LCK and PNB declare a US Provisional Patent Application in the name of University College Cork, Ireland (Louise Kenny and Philip Baker) “Detection of risk of pre-eclampsia” Application No USSN 61/288,465; RAN and MAB declares the following patent, which to date has not been licensed to a company: Blumenstein M, North RA, McMaster MT, Black MA, Kasabov NK, Cooper GJS. Biomarkers for prediction of pre-eclampsia and/or cardiovascular disease, PCT number WO/2009/108073. LP has a consultancy relationship with Tate and Lyle Research Advisory Group and is chairing a working party with ILSI Europe; both are outside the area of the submitted work.

Figures

None
Fig 1 Recruitment and flow of participants through study
None
Fig 2 Receiver operating characteristics curves based on independent predicted values from ten 10-fold cross validation runs of model of clinical risk factors at 15 weeks
None
Fig 3 Observed rate of pre-eclampsia compared with predicted probabilities of pre-eclampsia based on clinical risk factors model
None
Fig 4 Framework for specialist referral when estimated risk of pre-eclampsia is ≥15% in model or presence of clinical risk factor with abnormal result on uterine artery Doppler scan

Similar articles

Cited by

References

    1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99. - PubMed
    1. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-4. - PubMed
    1. National Institute for Health and Clinical Excellence. NICE clinical guideline 62. Antenatal care: routine care for the healthy pregnant woman. NICE, 2010.
    1. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565-7. - PMC - PubMed
    1. Chappell LC, Enye S, Seed P, Briley AL, Poston L, Shennan AH. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension 2008;51:1002-9. - PubMed

Publication types